Last reviewed · How we verify

NCT05390034: REFLEX

Improving Emotion Regulation Flexibility: Testing the Efficacy of an Emotion Regulation Program in College Students

Status unknown NA Last updated 7 November 2022
What this trial tests

NA trial testing ART in Anxiety Depression in 94 participants. Status unknown.

Timeline
1 September 2022
Primary endpoint
1 September 2022
1 December 2023

Quick facts

Lead sponsorUniversity Hospital, Grenoble
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment94
Start date1 September 2022
Primary completion1 September 2022
Estimated completion1 December 2023
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Grenoble

Who can join

Adults 18 to 30, any sex, with Anxiety Depression or Emotion Regulation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective of this RCT is to test the efficacy of an emotion regulation group program (i.e., ART program) in college students, compared to an active control group (i.e., relaxation program). Using multilevel analyses, we expect an improvement in anxious-depressive symptomatology for both groups. However, we expect the ART group to improve specifically on emotion regulation flexibility ability, and the last to be a mediative variable on mental health.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of ART

Trials testing the same drug.

Other recruiting trials for Anxiety Depression

Currently open trials in the same condition.

Other University Hospital, Grenoble trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05390034.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing